[go: up one dir, main page]

CN1341740A - A novel polypeptide-adenosine triphosphate dependent ribonucleic acid uncoiling enzyme 52.80 and polynucleotide for coding said polypeptide - Google Patents

A novel polypeptide-adenosine triphosphate dependent ribonucleic acid uncoiling enzyme 52.80 and polynucleotide for coding said polypeptide Download PDF

Info

Publication number
CN1341740A
CN1341740A CN 00125083 CN00125083A CN1341740A CN 1341740 A CN1341740 A CN 1341740A CN 00125083 CN00125083 CN 00125083 CN 00125083 A CN00125083 A CN 00125083A CN 1341740 A CN1341740 A CN 1341740A
Authority
CN
China
Prior art keywords
polypeptide
polynucleotide
rna helicase
atp
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN 00125083
Other languages
Chinese (zh)
Inventor
毛裕民
谢毅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Biowindow Gene Development Inc
Original Assignee
Shanghai Biowindow Gene Development Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Biowindow Gene Development Inc filed Critical Shanghai Biowindow Gene Development Inc
Priority to CN 00125083 priority Critical patent/CN1341740A/en
Publication of CN1341740A publication Critical patent/CN1341740A/en
Pending legal-status Critical Current

Links

Images

Landscapes

  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention discloses a novel polypeptide-ATP dependent RNA uncoiling enzyme 52.80, polynucleotide for coding said polypeptide and method for producing this polypeptide by using DNA recombination technology. Said invention also discloses method for curing several diseases, such as embryonic development deformity, tumor, diabetes, menstrual disorder, peptic ulcer, arrhythmia, anemia and epilepsy by using said polypeptide. Said invention also discloses an antagonist for resisting said polypeptide and its therapeutic action, and also discloses the application of polynucleotide for coding this novel ATP dependent RNA uncoiling enzyme 52.80.

Description

The polynucleotide of the rna helicases 52.80 that a kind of new polypeptide---Triphosaden relies on and this peptide species of coding
The invention belongs to biological technical field, specifically, the invention describes a kind of new polypeptide---the rna helicase enzyme 52.80 that ATP relies on, and the polynucleotide sequence of this polypeptide of encoding.The invention still further relates to the preparation method and the application of these polynucleotide and polypeptide.
Need various dissimilar enzymes to participate in the process such as duplicate of nucleic acid, wherein a class is a helicase.Nucleic acid helicase family utilizes the energy of hydrolysising ATP untwist double-stranded DNA and RNA.The dna helicase that ATP relies on such as provides dna replication dna, reparation, recombinates and transcribes at the necessary single stranded DNA of process.The rna helicase enzyme that ATP relies on provides mRNA shearing, translation and rrna to assemble necessary single stranded RNA.
From the rna helicase enzyme that bacterium, yeast or Mammals are originated very conservative sequence and structure are arranged all no matter be.This explanation rna helicase enzyme all plays an important role in various types of cells.For example, yeast Drs1 albumen participates in ribosome-RNA(rRNA) processing; Yeast TIF1, TIF2 and Mammals Eif-4A play a crucial role in the RNA translation initiation; The growth of people p68 antibody regulating cell and division (Ripmaster, T.L.et al. (1992) Proc.Natl.Acad.Sci.89:11131-35; Chang, T-Het al. (1990) Proc.Natl.Acad.Sci.87:1571-75).These rna helicase enzymes have that to be about 420 amino-acid residues be quite conservative, and comprise 4 structures: 1, sequence D X (4) A (4) GKT is the typical structure of the protein-bonded A structural domain of ATP; 2, " DEAD box " sequence (aspartic acid-L-glutamic acid-L-Ala-aspartic acid) is relevant with atpase activity; 3, the SAT sequence is relevant with the zone of untwisting of helicase; 4, sequence X/ORXGRXXR RNA in conjunction with the ATP hydrolysis in work (Pause, A.et al. (1993) Mol.Cell Biol.13:6789-98).
Rna helicase enzyme that ATP relies on and corresponding polynucleotide can be used for diagnosing, prevent and treatment cancer, nervous system disorders and disease of immune system.
People's of the present invention gene and rna helicase enzyme C end conservative region have 48% homology, 65% identity on protein level.So think that new gene of the present invention is the similar gene of a coding human RNA unwindase zymoprotein family, and have similar biological function.The rna helicase enzyme 52.80 that called after ATP relies on.And has a similar biological function.
Because rna helicase enzyme 52.80 albumen of ATP dependence play an important role in regulating body critical functions such as cell fission and fetal development as mentioned above, and believe and relate to a large amount of albumen in these regulate processes, thereby rna helicase enzyme 52.80 albumen that rely on of the ATP that always needs to identify more these processes of participation in this area, separation also provide the foundation for determining the effect of this albumen under healthy and morbid state.This albumen may constitute the basis of exploitation medical diagnosis on disease and/or curative, and it is very important therefore separating its coding DNA.
An object of the present invention is to provide isolating new polypeptide---rna helicase enzyme 52.80 that ATP relies on and fragment, analogue and derivative.
Another object of the present invention provides the polynucleotide of this polypeptide of coding.
Another object of the present invention provides the recombinant vectors of the polynucleotide of the rna helicase enzyme 52.80 that contains coding ATP dependence.
Another object of the present invention provides the genetically engineered host cell of the polynucleotide of the rna helicase enzyme 52.80 that contains coding ATP dependence.
Another object of the present invention provides the method for the rna helicase enzyme 52.80 of producing the ATP dependence.
Another object of the present invention provides at polypeptide of the present invention---the antibody of the rna helicase enzyme 52.80 that ATP relies on.Another object of the present invention has provided at polypeptide of the present invention---simulated compound, antagonist, agonist, the inhibitor of the rna helicase enzyme 52.80 that ATP relies on.
Another object of the present invention provides the method for the unusual relevant disease of rna helicase enzyme that diagnoses and treatment and ATP rely on 52.80.
The present invention relates to a kind of isolated polypeptide, this polypeptide is the people source, and it comprises: polypeptide or its examples of conservative variations, bioactive fragment or derivative with SEQ ID No.2 aminoacid sequence.Preferably, this polypeptide is the polypeptide with SEQ ID NO:2 aminoacid sequence.
The invention still further relates to a kind of isolating polynucleotide, it comprises a kind of nucleotide sequence or its variant that is selected from down group:
(a) coding has the polynucleotide of the polypeptide of SEQ ID No.2 aminoacid sequence;
(b) with polynucleotide (a) complementary polynucleotide;
(c) with (a) or polynucleotide sequence (b) have the polynucleotide of at least 70% homogeny.
More preferably, the sequence of these polynucleotide is be selected from down group a kind of: the sequence that (a) has 60-1502 position among the SEQ ID NO:1; (b) has the sequence of 1-1996 position among the SEQ ID NO:1.
The present invention relates to a kind of carrier that contains polynucleotide of the present invention, particularly expression vector in addition; The host cell that this carrier of a kind of usefulness is genetically engineered comprises the host cell of conversion, transduction or transfection; A kind of method for preparing polypeptide of the present invention of cultivating described host cell and reclaiming expression product that comprises.
The invention still further relates to a kind of can with polypeptid specificity bonded antibody of the present invention.
The invention still further relates to a kind of simulation, activation, antagonism of screening or suppress the method for the compound of rna helicase enzyme 52.80 protein-actives that ATP relies on, it comprises and utilizes polypeptide of the present invention.The invention still further relates to the compound that obtains with this method.
The invention still further relates to a kind of vitro detection and express the relevant disease or the method for disease susceptibility with rna helicase enzyme 52.80 abnormal proteins that ATP relies on, comprise the sudden change in polypeptide described in the detection of biological sample or its coded polynucleotide sequence, perhaps the amount or the biological activity of polypeptide of the present invention in the detection of biological sample.
The present invention also relates to a kind of pharmaceutical composition, it contains polypeptide of the present invention or its stand-in, activator, antagonist or inhibitor and pharmaceutically acceptable carrier.
The invention still further relates to polypeptide of the present invention and/or polynucleotide and be used for the treatment of cancer, developmental character disease or immunological disease or other purposes owing to the medicine of rna helicase enzyme 52.80 diseases that abnormal expression causes of ATP dependence in preparation.
Others of the present invention are because disclosing of the technology of this paper is conspicuous to those skilled in the art.
The following term of using in this specification sheets and claims has following implication unless stated otherwise:
" nucleotide sequence " is meant oligonucleotide, Nucleotide or polynucleotide and fragment or part, also can refer to genome or synthetic DNA or RNA, and they can be strand or two strands, represent sense strand or antisense strand.Similarly, term " aminoacid sequence " is meant oligopeptides, peptide, polypeptide or protein sequence and fragment or part.When " aminoacid sequence " among the present invention related to a kind of aminoacid sequence of naturally occurring protein molecule, this " polypeptide " or " protein " did not mean that aminoacid sequence are restricted to the complete natural amino acid relevant with described protein molecule.
Protein or polynucleotide " variant " are meant a kind of polynucleotide sequence that has the aminoacid sequence of one or more amino acid or Nucleotide change or encode it.Described change can comprise disappearance, insertion or the replacement of amino acid in aminoacid sequence or the nucleotide sequence or Nucleotide.Variant can have " conservative property " and change, and wherein the amino acid of Ti Huaning has structure or the chemical property similar with original acid, as replacing Isoleucine with leucine.Variant also can have non-conservation and change, as replacing glycine with tryptophane.
" disappearance " is meant the disappearance of in aminoacid sequence or nucleotide sequence one or more amino acid or Nucleotide.
" insertion " or " interpolation " is meant that the change in aminoacid sequence or nucleotide sequence causes comparing the increase of one or more amino acid or Nucleotide with naturally occurring molecule." replacement " is meant by different amino acid or Nucleotide and replaces one or more amino acid or Nucleotide.
" biological activity " is meant the protein of structure, regulation and control or biochemical function with natural molecule.Similarly, term " immunologic competence " be meant natural, reorganization or synthetic protein and fragment thereof in suitable animal or cell, induce specific immune response and with specific antibody bonded ability.
" agonist " is meant when the rna helicase enzyme 52.80 with the ATP dependence combines, thereby a kind of this protein that causes changes the molecule of regulating this protein active.Agonist can comprise the molecule of protein, nucleic acid, carbohydrate or any rna helicase enzyme 52.80 that other can rely in conjunction with ATP.
" antagonist " or " inhibition " be meant when when rna helicase enzyme 52.80 that ATP relies on combines, and a kind ofly seals or regulate the biologic activity of the rna helicase enzyme 52.80 that ATP relies on or the molecule of immunologic competence.Antagonist and inhibition can comprise the molecule of protein, nucleic acid, carbohydrate or any rna helicase enzyme 52.80 that other can rely in conjunction with ATP.
" adjusting " is meant that the function of the rna helicase enzyme 52.80 that ATP relies on changes, and comprises the change of any other biological property, function or the immune property of the rising of protein active or reduction, the change of binding characteristic and the rna helicase enzyme 52.80 that ATP relies on.
" pure basically " is meant and is substantially free of natural relative other albumen, lipid, carbohydrate or other material.The rna helicase enzyme 52.80 that those skilled in the art can rely on the purified technology of protein purifying ATP of standard.Basically the rna helicase enzyme 52.80 that pure ATP relies on can produce single master tape on the irreducibility polyacrylamide gel.The purity available amino end acid sequence of rna helicase enzyme 52.80 polypeptide that ATP relies on is analyzed.
" complementary " or " complementation " is meant under salt concn that allows and temperature condition by the natural combination of the polynucleotide of base pairing.For example, sequence " C-T-G-A " can combine with complementary sequence " G-A-C-T ".Complementation between two single chain molecules can be part or whole.Complementary degree between the nucleic acid chains has a significant effect for efficient of hybridizing between the nucleic acid chains and intensity.
" homology " is meant the complementary degree, can be portion homologous or complete homology." portion homologous " is meant a kind of part complementary sequence, and it can partly suppress the hybridization of complete complementary sequence and target nucleic acid at least.The inhibition of this hybridization can detect by hybridizing (Southern trace or Northern trace etc.) under the condition that reduces in the severity degree.Basically homologous sequence or hybridization probe can compete and suppress complete homologous sequence and target sequence the condition that reduces of severity degree under combine.This does not mean the conditions permit non-specific binding that the severity degree reduces because the conditional request two sequences that the severity degree reduces mutual be combined into specificity or selectivity interacts.
" homogeny percentage " be meant two or more amino acid or nucleotide sequence relatively in the same or analogous percentage of sequence.The available electron method is measured the homogeny percentage, as passing through MEGALIGN program (Lasergenesoftware package, DNASTAR, Inc., Madison Wis.).The MEGALIGN program can compare two or more sequences (Higgins, D.G. and P.M.Sharp (1988) Gene 73:237-244) according to diverse ways such as Cluster method.The Cluster method is organized the series arrangement cluster by checking the distance between all pairings with each.Then with each bunch with in pairs or become set of dispense.Homogeny percentage between two aminoacid sequences such as sequence A and the sequence B calculates by following formula:
The residue number of mating between sequence A and the sequence B
Figure A0012508300081
100
Interval residue number in the residue number-sequence B of interval in the residue number-sequence A of sequence A
Also can be by the Cluster method or with the homogeny percentage (Hein J., (1990) Methods in emzumology 183:625-645) between known method in this area such as the Jotun Hein mensuration nucleotide sequence.
" similarity " is meant the degree that the identical or conservative property of corresponding position amino-acid residue when arranging contrast between the aminoacid sequence replaces.For example be used for amino acid that conservative property replaces, electronegative amino acid can comprise aspartic acid and L-glutamic acid; Positively charged amino acid can comprise Methionin and arginine; Having uncharged head group has similar hydrophilic amino acid can comprise leucine, Isoleucine and Xie Ansuan; Glycine and L-Ala; L-asparagine and glutamine; Serine and Threonine; Phenylalanine and tyrosine.
" antisense " is meant and specific DNA or RNA sequence complementary nucleotide sequence." antisense strand " is meant and " sense strand " complementary nucleic acid chains.
" derivative " is meant HFP or encodes its chemical modification object of nucleic acid.This chemical modification object can be with alkyl, acyl group or the amino hydrogen atom of replacing.The nucleic acid derivative codified keeps the polypeptide of the main biological characteristics of natural molecule.
" antibody " is meant complete antibody molecule and fragment thereof, as Fa, F (ab ') 2And Fv, its energy specificity is in conjunction with the antigenic determinant of the rna helicase enzyme 52.80 of ATP dependence.
" humanized antibody " is meant that the aminoacid sequence in non-antigen binding domain territory is replaced and becomes more similar to people's antibody, but still keep original in active antibody.
" isolating " speech refers to material is shifted out among its original environment (for example, if spontaneous its natural surroundings that just refers to).Such as it is exactly not to be separated that spontaneous polynucleotide or polypeptide are present in the Live Animals, but same polynucleotide or polypeptide with some or all in natural system with it the material of coexistence separately be exactly isolating.Such polynucleotide may be the parts of a certain carrier, the part that also possible such polynucleotide or polypeptide are a certain composition.Since carrier or composition are not the compositions of its natural surroundings, they remain isolating.
As used herein, " isolating " are meant that material separates (if natural substance, primal environment promptly is a natural surroundings) from its primal environment.Do not have separation and purification as polynucleotide under the native state in the active somatic cell and polypeptide, but same polynucleotide or polypeptide as from native state with in other materials that exist separately, then for separation and purification.
As used herein, " the rna helicase enzyme 52.80 that isolating ATP relies on " is meant that the rna helicase enzyme 52.80 that ATP relies on is substantially free of natural relative other albumen, lipid, carbohydrate or other material.The rna helicase enzyme 52.80 that those skilled in the art can rely on the purified technology of protein purifying ATP of standard.Basically pure polypeptide can produce single master tape on non-reduced polyacrylamide gel.The purity of rna helicase enzyme 52.80 polypeptide that ATP relies on can be used amino acid sequence analysis.
The invention provides a kind of new polypeptide---the rna helicase enzyme 52.80 that ATP relies on, it is made up of the aminoacid sequence shown in the SEQID NO:2 basically.Polypeptide of the present invention can be recombinant polypeptide, natural polypeptides, synthetic polypeptide, preferred recombinant polypeptide.Polypeptide of the present invention can be the product of natural purifying, or the product of chemosynthesis, or uses recombinant technology to produce from protokaryon or eucaryon host (for example, bacterium, yeast, higher plant, insect and mammalian cell).The host used according to the recombinant production scheme, polypeptide of the present invention can be glycosylated, maybe can be nonglycosylated.Polypeptide of the present invention also can comprise or not comprise initial methionine residues.
The present invention also comprises fragment, derivative and the analogue of the rna helicase enzyme 52.80 that ATP relies on.As used herein, term " fragment ", " derivative " and " analogue " are meant biological function or the active polypeptide that keeps rna helicase enzyme that ATP of the present invention relies on 52.80 identical basically.The fragment of polypeptide of the present invention, derivative or analogue can be: (I) a kind of like this, wherein one or more amino-acid residues are replaced by conservative or non-conservative amino acid residues (preferably conservative amino acid residues), and the amino acid that replaces can be also can not encoded by genetic codon; Perhaps (II) is a kind of like this, and certain group on wherein one or more amino-acid residues is replaced by other group and comprises substituting group; Perhaps (III) is a kind of like this, and wherein mature polypeptide and another kind of compound (such as the compound that prolongs the polypeptide transformation period, for example polyoxyethylene glycol) merge; Perhaps (IV) is a kind of like this, wherein additional aminoacid sequence is integrated into mature polypeptide and the peptide sequence that forms (as leader sequence or secretion sequence or be used for the sequence or the proteinogen sequence of this polypeptide of purifying) by the elaboration of this paper, such fragment, derivative and analogue are considered within those skilled in the art's ken.
The invention provides isolating nucleic acid (polynucleotide), substantially the polynucleotide that have a polypeptide of SEQ ID NO:2 aminoacid sequence by coding are formed.Polynucleotide sequence of the present invention comprises the nucleotide sequence of SEQ ID NO:1.Polynucleotide of the present invention are to find from the cDNA library of people's fetal brain tissue.The polynucleotide sequence total length that it comprises is 1996 bases, its open reading frame 60-1502 480 amino acid of having encoded.Find relatively that according to amino acid sequence homologous the rna helicase enzyme that this polypeptide and ATP rely on has 48% homology, the rna helicase enzyme 52.80 that deducibility goes out this ATP dependence has the similar 26S Proteasome Structure and Function of rna helicase enzyme that ATP relies on.
Polynucleotide of the present invention can be dna form or rna form.Dna form comprises the DNA of cDNA, genomic dna or synthetic.DNA can be strand or double-stranded.DNA can be coding strand or noncoding strand.The coding region sequence of encoding mature polypeptide can be identical with the coding region sequence shown in the SEQ ID NO:1 or the varient of degeneracy.As used herein, " varient of degeneracy " are meant that in the present invention coding has protein or the polypeptide of SEQ ID NO:2, but with the differentiated nucleotide sequence of coding region sequence shown in the SEQ ID NO:1.
The polynucleotide of the mature polypeptide of coding SEQ ID NO:2 comprise: the encoding sequence that has only mature polypeptide; The encoding sequence of mature polypeptide and various additional code sequence; Encoding sequence of mature polypeptide (with optional additional code sequence) and non-coding sequence.
Term " polynucleotide of coded polypeptide " is meant polynucleotide that comprise this polypeptide of encoding and the polynucleotide that comprise additional code and/or non-coding sequence.
The invention still further relates to the varient of foregoing description polynucleotide, its coding has the polypeptide of identical aminoacid sequence or segment, analogue and the derivative of polypeptide with the present invention.The varient of these polynucleotide can be the allelic variant of natural generation or the varient that non-natural takes place.These nucleotide diversity bodies comprise and replace varient, deletion mutation body and insert varient.As known in the art, allelic variant is the replacement form of polynucleotide, and it may be replacement, disappearance or the insertion of one or more Nucleotide, but can be from not changing the function of its encoded polypeptides in fact.
The invention still further relates to and the polynucleotide (have at least 50% between two sequences, preferably have 70% homogeny) of sequence hybridization described above.The present invention be more particularly directed under stringent condition and the interfertile polynucleotide of polynucleotide of the present invention.In the present invention, " stringent condition " is meant: (1) than hybridization under low ionic strength and the comparatively high temps and wash-out, as 0.2 * SSC, and 0.1%SDS, 60 ℃; Or (2) hybridization the time adds and to use denaturing agent, as 50% (v/v) methane amide, 0.1% calf serum/0.1%Ficoll, 42 ℃ etc.; Or (3) only at the homogeny between the two sequences at least more than 95%, be more preferably 97% and just hybridize when above.And the polypeptide of interfertile polynucleotide encoding has identical biological function and activity with the mature polypeptide shown in the SEQ ID NO:2.
The invention still further relates to nucleic acid fragment with sequence hybridization described above.As used herein, " nucleic acid fragment " length contain 10 Nucleotide at least, better be 20-30 Nucleotide at least, be more preferably 50-60 Nucleotide at least, preferably more than at least 100 Nucleotide.Nucleic acid fragment also can be used for the amplification technique (as PCR) of nucleic acid to determine and/or to separate the polynucleotide of the rna helicase enzyme 52.80 that coding ATP relies on.
Polypeptide among the present invention and polynucleotide preferably provide with isolating form, more preferably are purified to homogeneous.
The special polynucleotide sequence of the rna helicase enzyme 52.80 that coding ATP of the present invention relies on can obtain with several different methods.For example, separate polynucleotide with hybridization technique well known in the art.These technology including, but not limited to: 1) with probe and genome or the hybridization of cDNA library to detect homologous polynucleotide sequence and 2) antibody screening of expression library to be to detect the polynucleotide passage of the clone with common structure feature.
Sequence dna fragment of the present invention also can obtain with following method: 1) separate double chain DNA sequence from genomic dna; 2) the chemical synthesising DNA sequence is to obtain the double-stranded DNA of described polypeptide.
In the above-mentioned method of mentioning, isolation of genomic DNA is least commonly used.The direct chemical of dna sequence dna is synthetic to be the method for often selecting for use.The more frequent method of selecting for use is the separation of cDNA sequence.The standard method that separates interested cDNA is from the donorcells separating mRNA of this gene of high expression level and carries out reverse transcription, forms plasmid or phage cDNA library.Extract the existing multiple proven technique of method of mRNA, test kit also can obtain (Qiagene) from commercial channels.And the construction cDNA library also is usual method (Sambrook, et al., MolecularCloning, A Laboratory Manual, Cold Spring Harbor Laboratory.New York, 1989).Also can obtain the cDNA library of commercial offers, as the different cDNA library of Clontech company.When being used in combination the polymeric enzyme reaction technology, even few expression product also can be cloned.
Available ordinary method is screened gene of the present invention from these cDNA libraries.These methods include, but is not limited to: (1) DNA-DNA or DNA-RNA hybridization; (2) appearance of marker gene function or forfeiture; (3) level of the transcript of the rna helicase enzyme 52.80 of mensuration ATP dependence; (4), detect the protein product of genetic expression by immunological technique or mensuration biologic activity.Aforesaid method can singly be used, but also several different methods combined utilization.
In (1) kind method, hybridizing used probe is and any a part of homology of polynucleotide of the present invention that at least 10 Nucleotide of its length better are at least 30 Nucleotide, are more preferably at least 50 Nucleotide, preferably at least 100 Nucleotide.In addition, within 2000 Nucleotide, preferable is within 1000 Nucleotide to the length of probe usually.Probe used herein is the dna sequence dna of chemosynthesis on the basis of gene order information of the present invention normally.Gene of the present invention itself or fragment are certainly as probe.The mark of dna probe can be used radio isotope, fluorescein or enzyme (as alkaline phosphatase) etc.
In (4) kind method, detect the protein product of rna helicase enzyme 52.80 genetic expressions of ATP dependence and can use immunological technique such as Western blotting, radioimmunoprecipitation, enzyme-linked immunosorbent assay (ELISA) etc.
Use method (Saiki, the et al.Science1985 of round pcr DNA amplification/RNA; 230:1350-1354) be optimized for acquisition gene of the present invention.When particularly being difficult to from the library, obtain the cDNA of total length, can preferably use RACE method (the terminal rapid amplifying method of RACE-cDNA), the primer that is used for PCR can suitably be selected according to polynucleotide sequence information of the present invention disclosed herein, and available ordinary method is synthetic.Available ordinary method is as the DNA/RNA fragment by gel electrophoresis separation and purifying amplification.
The gene of the present invention that obtains as mentioned above, perhaps the polynucleotide sequence of various dna fragmentations etc. can with ordinary method such as dideoxy chain termination (Sanger et al.PNAS, 1977,74:5463-5467) measure.This class polynucleotide sequence is measured also available commercial sequencing kit etc.In order to obtain the cDNA sequence of total length, order-checking need be carried out repeatedly.Sometimes need to measure a plurality of clones' cDNA sequence, just can be spliced into the cDNA sequence of total length.
The present invention also relates to comprise the carrier of polynucleotide of the present invention, and the host cell that produces through genetically engineered with carrier of the present invention or rna helicase enzyme 52.80 encoding sequences that directly rely on, and the method that produces polypeptide of the present invention through recombinant technology with ATP.
Among the present invention, the polynucleotide sequence of the rna helicase enzyme 52.80 that coding ATP relies on can be inserted in the carrier, contains the recombinant vectors of polynucleotide of the present invention with formation.Term " carrier " refers to that bacterial plasmid well known in the art, phage, yeast plasmid, vegetable cell virus, mammalian cell virus are as adenovirus, retrovirus or other carrier.The carrier of Shi Yonging includes but not limited in the present invention: and the expression vector based on the T7 promotor of in bacterium, expressing (Rosenberg, et al.Gene, 1987,56:125); The pMSXND expression vector of in mammalian cell, expressing (Lee and Nathans, J Bio Chem.263:3521,1988) and at the carrier that derives from baculovirus of expressed in insect cells.In a word, as long as can duplicate in host and stablize, any plasmid and carrier may be used to make up recombinant expression vector.A key character of expression vector is to contain replication origin, promotor, marker gene and translational control element usually.
Method well-known to those having ordinary skill in the art can be used to make up the dna sequence dna of the rna helicase enzyme 52.80 that contains coding ATP dependence and the expression vector of suitable transcribing/translational control element.These methods comprise (Sambroook, et al.Molecular Cloning, aLaboratory Manual, cold Spring Harbor Laboratory.New York, 1989) such as extracorporeal recombinant DNA technology, DNA synthetic technology, the interior recombinant technologys of body.Described dna sequence dna can effectively be connected on the suitable promotor in the expression vector, and is synthetic to instruct mRNA.The representative example of these promotors has: colibacillary lac or trp promotor; The P of lambda particles phage LPromotor; Eukaryotic promoter comprises LTRs and some other known may command gene expression promoter in prokaryotic cell prokaryocyte or eukaryotic cell or its virus of CMV immediate early promoter, HSV thymidine kinase promoter, early stage and late period SV40 promotor, retrovirus.Expression vector also comprises ribosome bind site that translation initiation is used and transcription terminator etc.Inserting enhancer sequence in carrier will make its transcribing in higher eucaryotic cells be enhanced.Enhanser is the cis acting factor that DNA expresses, and nearly 10 to 300 base pairs act on promotor transcribing with enhancing gene usually.Can for example be included in the SV40 enhanser of 100 to 270 base pairs of replication origin side in late period one, at the polyoma enhanser of replication origin side in late period one and adenovirus enhanser etc.
In addition, expression vector preferably comprises one or more selected markers, to be provided for selecting the phenotypic character of transformed host cells, cultivate Tetrahydrofolate dehydrogenase, neomycin resistance and the green fluorescent protein (GFP) of usefulness as eukaryotic cell, or be used for colibacillary tsiklomitsin or amicillin resistance etc.
Persons skilled in the art all know how to select appropriate carriers/transcriptional regulatory element (as promotor, enhanser etc.) and selected marker.
Among the present invention, the polynucleotide of the rna helicase enzyme 52.80 that coding ATP relies on or the recombinant vectors that contains these polynucleotide can transform or transduce into host cell, contain the genetically engineered host cell of these polynucleotide or recombinant vectors with formation.Term " host cell " refers to prokaryotic cell prokaryocyte, as bacterial cell; Or eukaryotic cell such as low, as yeast cell; Or higher eucaryotic cells, as mammalian cell.Representative example has: intestinal bacteria, streptomyces; Bacterial cell such as Salmonella typhimurium; Fungal cell such as yeast; Vegetable cell; Insect cell such as fruit bat S2 or Sf9; Zooblast such as CHO, COS or Bowes melanoma cells etc.
Can carry out with routine techniques well known to those skilled in the art with dna sequence dna of the present invention or the recombinant vectors transformed host cell that contains described dna sequence dna.When the host was prokaryotic organism such as intestinal bacteria, the competent cell that can absorb DNA can be used CaCl in exponential growth after date results 2Method is handled, and used step is well-known in this area.Alternative is to use MgCl 2If desired, transforming also the method for available electroporation carries out.When the host is an eukaryote, can select following DNA transfection method for use: coprecipitation of calcium phosphate method, perhaps conventional mechanical method such as microinjection, electroporation, liposome packing etc.
By the recombinant DNA technology of routine, utilize polynucleotide sequence of the present invention to can be used to express or produce rna helicase enzyme 52.80 (Science, 1984 of the ATP dependence of reorganization; 224:1431).In general following steps are arranged:
(1). the polynucleotide (or varient) of the rna helicase enzyme 52.80 that relies on coding of the present invention people ATP, or with the recombinant expression vector that contains these polynucleotide proper host cell that transforms or transduce;
(2). in suitable medium, cultivate host cell;
(3). separation, protein purification from substratum or cell.
In step (2), according to used host cell, used substratum can be selected from various conventional substratum in the cultivation.Under the condition that is suitable for the host cell growth, cultivate.After host cell grows into suitable cell density, induce the promotor of selection with suitable method (as temperature transition or chemical induction), cell is cultivated for some time again.
In step (3), recombinant polypeptide can wrap and be expressed or be secreted into the extracellular in cell or on cytolemma.If desired, can utilize its physics, the separating by various separation methods with other characteristic and the albumen of purification of Recombinant of chemistry.These methods are well-known to those skilled in the art.These methods include, but are not limited to: conventional renaturation is handled, protein precipitant is handled (salt analysis method), centrifugal, the broken bacterium of infiltration, the combination of ultrasonication, super centrifugal, sieve chromatography (gel-filtration), adsorption chromatography, ion exchange chromatography, high performance liquid chromatography (HPLC) and other various liquid chromatography (LC) technology and these methods.
The antagonist of polypeptide of the present invention and this polypeptide, agonist and inhibitor can be directly used in disease treatment, for example, can treat malignant tumour, adrenal gland defect, tetter, all kinds of inflammation, HIV infection and immunological disease etc.
The human RNA unwindase enzyme is the untwist proteolytic ferment of RNA of a kind of energy that utilizes hydrolysising ATP in the human body.It plays an important role in processes such as mRNA shearing, translation and rrna assembling.Its abnormal expression can cause that processes such as mRNA shearing, translation and rrna assembling get muddled, and then causes the generation of relative disease.
Polypeptide of the present invention and human RNA unwindase enzyme are the rna helicase enzymes that ATP relies on, the characteristic sequence that contains this protein family, both have similar biological function, this polypeptide unconventionality expression in vivo can cause that processes such as mRNA shearing, translation and rrna assembling get muddled, and then cause fetal development deformity, protein metabolism disorder to get muddled and the generation of tumor disease, these diseases include but not limited to:
Common fetal development deformity
One. the common deformity of face, neck and four limbs:
1. harelip (the most common, as can to split and cleft palate) with alveolar process, cleft palate, prosopoanoschisis, neck capsule, neck fistula etc.;
2. the common deformity of four limbs: 1) deficiency of skeletal limb:
Laterally lack as (congenital manomelia): no arm, no forearm, no hand, aphalangia, acnemia, no toe etc.; Vertically lack as: upper limbs oar/ulnar side lack as, lower limb shin/diseased side lack as etc.;
Sea dog sample hand/foot deformity etc.; 2) limbs dysdifferentiation: certain piece muscle or muscle group lack as, arthrodyasplasia, bone malformation, bone merges, many fingers (toe), and refer to (toe) deformity, talipes varus etc.; Two. the common deformity of Digestive tract:
Thyroglossal cyst, alimentary canal locking or narrow, ileal diverticulum, umbilical fistula, congenital umbillical bernia, congenital no god
Through joint property megacolon, the transposition of stumbling of imperforate anus, intestines is unusual, biliary atresia, annular pancreas etc.; Three. the common deformity of respiratory system: larynx tracheostenosis/locking, tracheo esophageal fistula, hyaline membrane disease, unilateral lung is not
Ectopic lung lobe, congenital pulmonary cyst, atelectasis etc. take place; Four. the common deformity of urinary system: polycystic kidney, ectopical kidney, horse tellurium kidney, double ureter, urachal fistula, bladder
Turn up etc.; Five. the common deformity of reproductive system: cryptorchidism, congenital inguinal hernia, duplex uterus, vaginal atresia is under the urethra
Split, true/pseudohermaphroditism, testicular feminization syndrome etc.; Six. the common deformity of cardiovascular systems: atrial septal defect, ventricular septal defect, arterial trunk is separated unusually (initiatively
Arteries and veins and pulmonary artery dislocation, aorta or pulmonic stenosis), patent ductus arteriosus etc.; Seven. neural common deformity: neural tube defect (anencephalia, myeloschisis, the bulging of spinal cord spinal meninges,
The bulging of hydrencephalomeningocele film brain), brain inside/outside hydrocephalus etc.; Eight. the common deformity of eye, ear: iridocoloboma, persistent pupillary membrane, congenital cataract, congenital blue or green light
Eye, solely/nothing/microphthalmia, congenital deafness, aural deformity etc.; The various kinds of tumor of organizing: one. epithelium:
Papilloma, squamous cell carcinoma [skin, nasopharynx, larynx, uterine neck], adenoma (cancer) [mammary gland, Tiroidina], sticking/serous cystadenoma (cancer) [ovary], rodent cancer [head-face skin], (pernicious) polytypism adenoma [prolonging gland], papilloma, transitional epithelium cancer [bladder, renal plevis] etc.; Two. mesenchymal tissue:
Fiber (meat) knurl [four limbs], (pernicious) fibrous histiocytoma [four limbs], fat (meat) knurl [subcutis, lower limb, behind the peritonaeum], unstriated muscle (meat) knurl [uterus and stomach and intestine], voluntary muscle (meat) knurl [neck, genitourinary tract, four limbs], blood vessel (meat) knurl, lymphatic vessel (meat) knurl [skin, subcutis, tongue, lip], bone (meat) knurl [skull, long bone], (evil) property giant cell tumor [thigh/shin/upper end of humerus], cartilage (meat) knurl [brothers' short bone, basin/rib/thigh/upper arm/shoulder blade], near synovial membrane (meat) knurl [knee/ankle/wrist/shoulder/elbow joint], (evil) property mesothelioma [chest/peritonaeum] etc.; Three. lymphohematopoietic tissue delivered:
Malignant lymphoma [neck, mediastinum, mesentery and retroperitoneal lymph node], various leukemia [lymphohematopoietic tissue delivered], multiple myeloma [vertebra/chest/rib/skull and long bone] etc.; Four. nervous tissue:
Nerve fiber (meat) knurl [whole body cutaneous nerve/deep nerve and internal organ], (pernicious) schwannoma [head, neck, four limbs etc. are located nerve], (pernicious) glioma [brain], medulloblastoma [cerebellum], (pernicious) meningioma [meninx], joint neurocytoma/neuroblastoma [behind mediastinum and the peritonaeum/adrenal medulla] etc.; Five. other tumours:
Black mole, malignant melanoma [skin, mucous membrane], (pernicious) hydatidiform mole, chorioepithelioma [uterus], (pernicious) sustenticular cell, Leydig's cell tumor, (pernicious) GCT [ovary, testis], spermocytoma [testis], dysgerminoma [ovary], embryonal carcinoma [testis, ovary], (pernicious) teratoma [ovary, testis, mediastinum and sacrococcygeal region] etc.; Protein metabolism disorder relative disease protein metabolism disorder can influence the following major physiological function of protein, and then causes the generation of relative disease: one. and human body energy is provided, keeps tissue growth, renewal and repairing:
Amyotrophy, tetraparesis, health is become thin, and severe patient can be " cachexy " performance; Two. produce some physiologically active substances, as hormone, antibody, amine etc.: 1. the dysfunction of protein peptide parahormone can cause following disease to take place:
1) Regular Insulin and hyperglycemic-glycogenolytic factor: diabetes, hypoglycemia etc.;
2) hypothalamic and pituitary hormone: gigantosoma, nanism, acromegaly, hypercortisolism (Cushing's syndrome), the primary aldosteronism, the secondary chronic adrenocortical insufficiency, hyperthyroidism, and hypothyroidism (cretinism, the juvenile form first subtracts, the adult first subtracts), man/women infertility, menoxenia (dysfunctional uterine hemorrhage, amenorrhoea, polycystic ovary syndrome, premenstrualtension syndrome, climacteric syndrome), sexual development obstacle, diabetes insipidus, antidiuretic hormone are secreted improper syndromes, and lactation is unusual etc.;
3) parathyroid hormone: hyperparathyroidism, hypoparathyroidism etc.;
4) gastrointestinal hormone: peptide ulceration, chronic indigestion, chronic gastritis etc.; 2. the amine substance metabolism disorder can cause following disease to take place: irregular pulse, shock, psychiatric disorder, epilepsy, tarantism, hepatogenic encephalopathy (norepinephrine, γ-An Jidingsuan, serotonin, glutamine), motion sickness, I-metallergy disease (urticaria, spring fever, allergic rhinitis, allergic), peptide ulceration (histamine), hypercholesterolemia (taurine), tumour (polyamines) etc.; 3. various infection easily take place in the antibody defective: septicemia, purulent meningitis, pneumonia, trachitis, otitis media, pyoderma etc.; Three. some proteinic special physiological effect: various hemoglobinopathies (anaemia, jaundice, histanoxia cause organic acidemia), various coagulation factor deficiencies (hemorrhage), myospasm, flesh pressure, myoplegia (Actin muscle), hyperlipoproteinemia etc.; Comprehensively above-mentioned, the antagonist of polypeptide of the present invention and this polypeptide, agonist and inhibitor can be directly used in multiple treatment of diseases, diseases such as for example fetal development deformity, tumour, diabetes, menoxenia, peptide ulceration, irregular pulse, anaemia, epilepsy.
The present invention also provides SCREENED COMPOUND to identify the method that improves (agonist) or check the medicament of the rna helicase enzyme 52.80 that (antagonist) ATP relies on.Agonist improves rna helicase enzyme 52.80 that ATP relies on biological function such as stimulate cellular proliferation, and antagonist prevention disorder such as the various cancer relevant with cell hyperproliferation with treatment.For example, can be in the presence of medicine, with mammalian cell or the film preparation of expressing the rna helicase enzyme 52.80 that ATP relies on cultivate with the rna helicase enzyme 52.80 that the ATP of mark relies on.Measure the medicine raising then or check this interactional ability.
The antagonist of the rna helicase enzyme 52.80 that ATP relies on comprises antibody, compound, acceptor disappearance thing and the analogue etc. that filter out.The antagonist of the rna helicase enzyme 52.80 that ATP relies on can combine and eliminate its function with the rna helicase enzyme 52.80 that ATP relies on, or suppresses the generation of this polypeptide, or combines with the avtive spot of this polypeptide and to make this polypeptide can not bring into play biological function.
In screening during as the compound of antagonist, the rna helicase enzyme 52.80 that ATP can be relied on adds during bioanalysiss measure, and determines by measuring between rna helicase enzyme 52.80 that compound relies on ATP and its acceptor interactional influence whether compound is antagonist.With the same quadrat method of above-mentioned SCREENED COMPOUND, can filter out the acceptor disappearance thing and the analogue of antagonist action.The rna helicase enzyme 52.80 bonded peptide molecules that can rely on ATP can be incorporated into the rondom polypeptide storehouse that solid formation forms by the various amino acid that may make up by screening and obtain.During screening, rna helicase enzyme 52.80 molecules of generally tackling the ATP dependence carry out mark.
The invention provides and use polypeptide, and fragment, derivative, analogue or their cell are as the method for antigen with production antibody.These antibody can be polyclonal antibody or monoclonal antibody.The present invention also provides the antibody of rna helicase enzyme 52.80 antigenic determinants that rely at ATP.These antibody include, but is not limited to: the fragment that polyclonal antibody, monoclonal antibody, chimeric antibody, single-chain antibody, Fab fragment and Fab expression library produce.
The method of the rna helicase enzyme 52.80 direct injection immune animals (as rabbit, mouse, rat etc.) that the available ATP of the production of polyclonal antibody relies on obtains, and multiple adjuvant can be used for the enhancing immunity reaction, includes but not limited to freund's adjuvant etc.The technology of the monoclonal antibody of the rna helicase enzyme 52.80 that preparation ATP relies on includes but not limited to hybridoma technology (Kohler and Milstein.Nature, 1975,256:495-497), three knurl technology, people B-quadroma technology, EBV-hybridoma technology etc.With the variable region bonded chimeric antibody in human constant region and inhuman source can with existing technology production (Morrison et al, PNAS, 1985,81:6851).And the technology of existing manufacture order chain antibody (U.S.Pat No.4946778) also can be used for producing the single-chain antibody of the rna helicase enzyme 52.80 that anti-ATP relies on.
The antibody of the rna helicase enzyme 52.80 that anti-ATP relies on can be used in the immunohistochemistry technology, detects the rna helicase enzyme 52.80 that the ATP in the biopsy specimen relies on.
The also available labelled with radioisotope of rna helicase enzyme 52.80 bonded monoclonal antibodies with ATP relies on injects in the body and can follow the tracks of its position and distribution.This radiolabeled antibody can be used as a kind of atraumatic diagnostic method and is used for the location of tumour cell and has judged whether transfer.
Antibody also can be used for designing the immunotoxin at a certain privileged sites in the body.The monoclonal antibody of rna helicase enzyme 52.80 high-affinities that rely on as ATP can with bacterium or plant poison (as diphtheria toxin, ricin, abrine etc.) covalent attachment.A kind of usual method is with sulfydryl linking agent such as SPDP, attacks the amino of antibody, by the exchange of disulfide linkage, toxin is incorporated on the antibody, and this hybrid antibody can be used for killing rna helicase enzyme 52.80 positive cells that ATP relies on.
The disease that antibody among the present invention can be used for treating or prevention and ATP rely on rna helicase enzyme 52.80 is relevant.The antibody that gives suitable dosage can stimulate or block the generation or the activity of the rna helicase enzyme 52.80 of ATP dependence.
The invention still further relates to diagnostic testing process quantitative and rna helicase enzyme 52.80 levels that detection and localization ATP relies on.These tests are known in the art, and comprise that FISH measures and radioimmunoassay.Rna helicase enzyme 52.80 levels that the ATP that detected in the test relies on, the disease that the importance of rna helicase enzyme 52.80 in various diseases that can rely on the ATP that lays down a definition and the rna helicase enzyme 52.80 that is used to diagnose ATP to rely on work.
Polypeptide of the present invention also can be used as the peptide spectrum analysis, for example, the polypeptide available physical, chemistry or enzyme carry out the specificity cutting, and carries out the two-dimentional or three-dimensional gel electrophoresis analysis of one dimension, be more preferably and carry out mass spectroscopy.
The polynucleotide of the rna helicase enzyme 52.80 that coding ATP relies on also can be used for multiple therapeutic purpose.Gene therapy technology can be used for treating because cell proliferation, growth or the metabolic disturbance due to the nothing expression of the rna helicase enzyme 52.80 that ATP relies on or the unusual/non-activity expression.The gene therapy vector (as virus vector) of reorganization can be designed for the rna helicase enzyme 52.80 of the ATP dependence of expressing variation, to suppress rna helicase enzyme 52.80 activity that endogenic ATP relies on.For example, the rna helicase enzyme 52.80 that a kind of ATP of variation relies on can be the rna helicase enzyme 52.80 that ATP shortening, that lacked signal conduction function territory relies on, though can combine with the substrate in downstream, lacks signaling activity.Therefore the gene therapy vector of reorganization can be used for treating rna helicase enzyme 52.80 expression of ATP dependence or the disease of active caused by abnormal.Deriving from the polynucleotide that the expression vector of virus such as retrovirus, adenovirus, adeno-associated virus (AAV), hsv, parvovirus etc. can be used for rna helicase enzyme 52.80 that coding ATP is relied on is transferred in the cell.The method of recombinant viral vector that structure carries the polynucleotide of the rna helicase enzyme 52.80 that coding ATP relies on is found in existing document (Sambrook, et al.).The polynucleotide of the rna helicase enzyme 52.80 of reorganization coding ATP dependence can be packaged in the liposome and be transferred in the cell in addition.
Polynucleotide import tissue or intracellular method comprises: directly be injected into polynucleotide in the in-vivo tissue; Or external by carrier (as virus, phage or plasmid etc.) earlier with the polynucleotide transfered cell in, again cell is transplanted in the body etc.
Suppress the oligonucleotide (comprising sense-rna and DNA) of rna helicase enzyme 52.80 mRNA that ATP relies on and ribozyme also within the scope of the invention.Ribozyme is the enzyme sample RNA molecule that a kind of energy specificity is decomposed specific RNA, and its mechanism of action is to carry out the endonuclease effect after ribozyme molecule and the hybridization of complementary target RNA-specific.The RNA of antisense and DNA and ribozyme can obtain with existing any RNA or DNA synthetic technology, as the technology widespread use of solid phase phosphoamide chemical synthesis synthetic oligonucleotide.Antisense rna molecule can be transcribed acquisition by the dna sequence dna of this RNA that encodes in external or body.This dna sequence dna has been incorporated into the downstream of rna polymerase promoter of carrier.In order to increase the stability of nucleic acid molecule, available several different methods is modified it, and as increasing the sequence length of both sides, the connection between the ribonucleoside is used phosphoric acid thioester bond or peptide bond but not phosphodiester bond.
The polynucleotide of the rna helicase enzyme 52.80 that coding ATP relies on can be used for the diagnosis of the relative disease of the rna helicase enzyme 52.80 that relies on ATP.Whether or the unconventionality expression of the rna helicase enzyme 52.80 that ATP relies under morbid state the expression that the polynucleotide of the rna helicase enzyme 52.80 that coding ATP relies on can be used for detecting the rna helicase enzyme 52.80 that ATP relies on.As the dna sequence dna of the rna helicase enzyme 52.80 of the ATP dependence of encoding can be used for biopsy specimen is hybridized to judge the expression situation of the rna helicase enzyme 52.80 that ATP relies on.Hybridization technique comprises the Southern blotting, Northern blotting, in situ hybridization etc.These technological methods all are disclosed mature technologies, and relevant test kit all can obtain from commercial channels.Part or all of polynucleotide of the present invention can be used as probe stationary on microarray (Microarray) or DNA chip (being called " gene chip " again), is used for analyzing the differential expression analysis and the gene diagnosis of tissue gene.The rna helicase enzyme 52.80 special primers that rely on ATP carry out the transcription product that RNA-polymerase chain reaction (RT-PCR) amplification in vitro also can detect the rna helicase enzyme 52.80 of ATP dependence.
The sudden change that detects rna helicase enzyme 52.80 genes that ATP relies on also can be used for diagnosing the relevant disease of rna helicase enzyme that ATP relies on 52.80.The form of rna helicase enzyme 52.80 sudden changes that ATP relies on comprises that point mutation that rna helicase enzyme 52.80 dna sequence dnas that rely on normal wild type ATP compare, transposition, disappearance, reorganization and other are any unusual etc.Available existing technology such as Southern blotting, dna sequence analysis, PCR and in situ hybridization detect sudden change.In addition, sudden change might influence proteic expression, therefore can judge indirectly that with Northern blotting, Western blotting gene has or not sudden change.
Sequence of the present invention identifies it also is valuable to karyomit(e).This sequence can be specifically at certain bar human chromosome particular location and and can with its hybridization.At present, need to identify the concrete site of each gene on the karyomit(e).Now, have only chromosomal marker thing seldom to can be used for the marker chromosomes position based on actual sequence data (repetition polymorphism).According to the present invention, for these sequences are associated with disease related gene, its important the first step is positioned these dna sequence dnas on the karyomit(e) exactly.
In brief, prepare PCR primer (preferred 15-35bp), sequence can be positioned on the karyomit(e) according to cDNA.Then, these primers are used for the somatocyte hybrid cell that the PCR screening contains each bar human chromosome.Have only those hybrid cells that contain corresponding to the people's gene of primer can produce the fragment of amplification.
The PCR localization method of somatocyte hybrid cell is that DNA is navigated to concrete chromosomal quick method.Use Oligonucleolide primers of the present invention,, can utilize one group to realize inferior location from specific chromosomal fragment or a large amount of genomic clone by similar approach.Other the similar strategy that can be used for chromosomal localization comprises in situ hybridization, uses the karyomit(e) prescreen and the hybridization preliminary election of the airflow classification of mark, thereby makes up the special cDNA storehouse of karyomit(e).
The cDNA clone is carried out fluorescence in situ hybridization (FISH) with Metaphase Chromosome, can in a step, accurately carry out chromosomal localization.The summary of this technology is referring to Verma etc., Human Chromosomes:a Manualof Basic Techniques, Pergamon Press, New York (1988).
In case sequence is positioned to chromosome position accurately, the physical location of this sequence on karyomit(e) just can be associated with the gene map data.These data for example are found in, V.Mckusick, Mendelian Inheritancein Man (can by with the online acquisition of Johns Hopkins University Welch Medical Library).Can pass through linkage analysis then, determine gene and navigated to relation between the disease on the chromosomal region already.
Then, need to measure ill and not cDNA between diseased individuals or genome sequence difference.If observe certain sudden change in some or all of diseased individuals, and this sudden change is not observed in any normal individual, then this sudden change may be the cause of disease of disease.More ill and diseased individuals not is usually directed at first seek the variation of structure in the karyomit(e), as from the horizontal visible of karyomit(e) or use based on detectable disappearance of the PCR of cDNA sequence or transposition.Resolving power according to present physical mapping and assignment of genes gene mapping technology, being accurately positioned to the cDNA of the chromosomal region relevant with disease, can be a kind of (the supposing that 1 megabasse mapping resolving power and every 20kb are corresponding to a gene) between 50 to 500 potential Disease-causing genes.
Polypeptide of the present invention, polynucleotide and stand-in thereof, agonist, antagonist and inhibitor and suitable pharmaceutical carrier combination back can be used.These carriers can be water, glucose, ethanol, salt, damping fluid, glycerine and their combination.Composition comprises the polypeptide or the antagonist of safe and effective amount and carrier and the vehicle that does not influence effect of drugs.These compositions can be used as medicine and are used for disease treatment.
The present invention also provides medicine box or the test kit that contains one or more containers, and one or more medicinal compositions compositions of the present invention are housed in the container.With these containers, can have by the given indicative prompting of government authorities of making, using or selling medicine or biological products, the government authorities that this prompting reflects production, uses or sells permits it to use on human body.In addition, polypeptide of the present invention can be used in combination with other treatment compound.
Pharmaceutical composition can be with mode administration easily, as by in part, intravenously, intraperitoneal, intramuscular, subcutaneous, the nose or the route of administration of intracutaneous.The rna helicase enzyme 52.80 that ATP relies on comes administration with the amount that treats and/or prevents concrete indication effectively.The amount and the dosage range that are applied to the rna helicase enzyme 52.80 that patient's ATP relies on will depend on many factors, as administering mode, person's to be treated healthiness condition and diagnostician's judgement.
Following accompanying drawing is used to illustrate specific embodiments of the present invention, and is not used in qualification by the scope of the invention that claims defined.
Fig. 1 is the rna helicase enzyme 52.80 of ATP dependence of the present invention and the amino acid sequence homology comparison diagram of the rna helicase enzyme that ATP relies on.The top sequence is the rna helicase enzyme 52.80 that ATP relies on, and the below sequence is the rna helicase enzyme that ATP relies on.Same amino acid represents with monocase amino acid that between two sequences similar amino acid is represented with "+".
Fig. 2 is the polyacrylamide gel electrophoresis figure (SDS-PAGE) of the rna helicase enzyme 52.80 of isolating ATP dependence.52.80kDa be proteinic molecular weight.The arrow indication is isolated protein band.
Below in conjunction with specific embodiment, further set forth the present invention.Should be understood that these embodiment only to be used to the present invention is described and be not used in and limit the scope of the invention.The experimental technique of unreceipted actual conditions in the following example, usually according to people such as normal condition such as Sambrook, molecular cloning: laboratory manual (New York:Cold SpringHarbor Laboratory Press, 1989) condition described in, or the condition of advising according to manufacturer.The clone of the rna helicase enzyme 52.80 that embodiment 1:ATP relies on
Extract the total RNA of people's tire brain with guanidinium isothiocyanate/phenol/chloroform single stage method.From total RNA, separate poly (A) mRNA with Quik mRNA Isolation Kit (Qiegene company product).2ug poly (A) mRNA forms cDNA through reverse transcription.CDNA fragment orientation is inserted on the multiple clone site of pBSK (+) carrier (Clontech company product) with Smart cDNA clone's test kit (available from Clontech), transforms DH5 α, bacterium forms the cDNA library.Measure all clones' 5 ' and 3 ' terminal sequence with Dyeterminate cycle reaction sequencing kit (Perkin-Elmer company product) and ABI 377 automatic sequencers (Perkin-Elmer company).CDNA sequence and the existing public dna sequence data storehouse (Genebank) measured are compared, found that the cDNA sequence of one of them clone 1214e03 is new DNA.By synthetic a series of primers the contained insertion cDNA fragment of this clone is carried out two-way mensuration.The result shows, the contained full-length cDNA of 1214e03 clone is 1996bp (shown in Seq ID NO:1), from 60bp to 1502bp the open reading frame (ORF) of a 1443bp, the new protein (shown in SeqID NO:2) of encoding arranged.We are with this clone's called after pBS-1214e03, the rna helicase enzyme 52.80 that encoded protein matter called after ATP relies on.Embodiment 2:cDNA clone's homology retrieval
The sequence and the encoded protein sequence thereof of the rna helicase enzyme 52.80 that ATP of the present invention is relied on are with Blast program (Basiclocal Alignment search tool) [Altschul, SF et al.J.Mol.Biol.1990; 215:403-10], carry out the homology retrieval at databases such as Genbank, Swissport.The gene that rna helicase enzyme 52.80 homologys that rely on ATP of the present invention are the highest is the rna helicase enzyme that a kind of known ATP relies on, and its encoded protein number is AC007660 in the access of Genbank.Protein homology the results are shown in Fig. 1, both height homologies, and its homogeny is 48%; Similarity is 65%.Embodiment 3: the gene of using the rna helicase enzyme 52.80 of RT-PCR method clones coding ATP dependence
Total RNA is a template with fetus brain cell, is that primer carries out the synthetic cDNA of reverse transcription reaction with oligo-dT, with behind the test kit purifying of Qiagene, carries out pcr amplification with following primer:
Primer1：5’-GGGGCCCAGCAGTCTGCGCACCGG-3’(SEQ?ID?NO：3)
Primer2：5’-ACGAAAGTCTACATTTATTTGGGA-3’(SEQ?ID?NO：4)
Primer1 is the forward sequence that begins of 1bp that is positioned at the 5 ' end of SEQ ID NO:1;
Primer2 be SEQ ID NO:1 in 3 ' end reverse sequence.
The condition of amplified reaction: in the reaction volume of 50 μ l, contain 50mmol/L KCl, 10mmol/LTris-Cl, (pH8.5), 1.5mmol/L MgCl 2, 200 μ mol/L dNTP, 10pmol primer, the Taq archaeal dna polymerase of 1U (Clontech company product).Go up by 25 cycles of following conditioned response at PE9600 type DNA thermal cycler (Perkin-Elmer company): 94 ℃ of 30sec; 55 ℃ of 30sec; 72 ℃ of 2min.When RT-PCR, establish the blank negative contrast of positive contrast of β-actin and template simultaneously.Amplified production is connected to (Invitrogen company product) on the pCR carrier with the test kit purifying of QIAGEN company with TA clone test kit.The dna sequence analysis result shows that the dna sequence dna of PCR product and the 1-1996bp shown in the SEQ ID NO:1 are identical.Rna helicase enzyme 52.80 expression of gene that embodiment 4:Northern blotting ATP Analysis relies on:
Extract total RNA[Anal.Biochem 1987,162,156-159 with single stage method].This method comprises acid guanidine thiocyanate phenol-chloroform extracting.Promptly use 4M guanidinium isothiocyanate-25mM Trisodium Citrate, 0.2M sodium acetate (pH4.0) carries out homogenate to tissue, adds the phenol of 1 times of volume and the chloroform-primary isoamyl alcohol (49: 1) of 1/5 volume, and is centrifugal after mixing.The sucking-off aqueous phase layer adds Virahol (0.8 volume) and with the centrifugal RNA precipitation that obtains of mixture.With RNA precipitation 70% washing with alcohol that obtains, dry and soluble in water.With 20 μ g RNA, on 1.2% sepharose that contains 20mM 3-(N-morpholino) propanesulfonic acid (pH7.0)-5mM sodium acetate-1mM EDTA-2.2M formaldehyde, carry out electrophoresis.Be transferred on the nitrocellulose filter then.With α- 32P dATP prepares by random priming 32The dna probe of P-mark.Used dna probe is rna helicase enzyme 52.80 coding region sequences (60bp to 1502bp) that the ATP of pcr amplification shown in Figure 1 relies on.Probe (about 2 * 10 with the 32P-mark 6Cpm/ml) spend the night in 42 ℃ of hybridization in a solution with the nitrocellulose filter that has shifted RNA, this solution comprises 50% methane amide-25mM KH 2PO 4(pH7.4)-5 * SSC-5 * Denhardt ' s solution and 200 μ g/ml salmon sperm DNAs.After the hybridization, filter membrane is washed 30min in 55 ℃ in 1 * SSC-0.1%SDS.Then, analyze with quantitative with Phosphor Imager.Embodiment 5: vivoexpression, separation and the purifying of the rna helicase enzyme 52.80 that reorganization ATP relies on
According to SEQ ID NO:1 and coding region sequence shown in Figure 1, design a pair of specificity amplification primer, sequence is as follows:
Primer3：5’-CCCCATATGATGGCAGCCGCCGACGGTTCGCTC-3’(Seq?ID?No：5)
Primer4：5’-CATGGATCCTCACGTGCAAAGAAGGACGCCTCT-3’(Seq?ID?No：6)
5 ' end of these two sections primers contains NdeI and BamHI restriction enzyme site respectively, be respectively the encoding sequence of target gene 5 ' end and 3 ' end thereafter, NdeI and BamHI restriction enzyme site are corresponding to expression vector plasmid pET-28b (+) (Novagen company product, Cat.No.69865.3) the selectivity restriction enzyme site on.With the pBS-1214e03 plasmid that contains the total length goal gene is template, carries out the PCR reaction.The PCR reaction conditions is: contain pBS-1214e03 plasmid 10pg, primer Primer-3 and Primer-4 among the cumulative volume 50 μ l and be respectively 10pmol, Advantage polymerase Mix (Clontech company product) 1 μ l.Loop parameter: 94 ℃ of 20s, 60 ℃ of 30s, 68 ℃ of 2min, totally 25 circulations.Respectively amplified production and plasmid pET-28 (+) are carried out double digestion with NdeI and BamHI, reclaim big fragment respectively, and connect with the T4 ligase enzyme.Connect product and transform, after the dull and stereotyped overnight incubation of the LB that contains kantlex (final concentration 30 μ g/ml), use the colony polymerase chain reaction (PCR) method screening positive clone, and check order with the big enterobacterial DH5 of Calcium Chloride Method α.Select the correct positive colony of sequence (pET-1214e03) with Calcium Chloride Method with recombinant plasmid transformed e. coli bl21 (DE3) plySs (Novagen company product).In the LB liquid nutrient medium that contains kantlex (final concentration 30 μ g/ml), host bacterium BL21 (pET-1214e03) is cultured to logarithmic phase at 37 ℃, adds IPTG to final concentration 1mmol/L, continues to cultivate 5 hours.Centrifugal collection thalline, through the broken bacterium of ultrasonic wave, centrifugal collection supernatant with carrying out chromatography with 6 Histidines (6His-Tag) bonded affinity column His.Bind Quick Cartridge (Novagen company product), has obtained the rna helicase enzyme 52.80 of the target protein ATP dependence of purifying.Through the SDS-PAGE electrophoresis, obtain a single band (Fig. 2) at the 52.80kDa place.This band is transferred on the pvdf membrane carries out the n terminal amino acid sequential analysis with the Edams hydrolysis method, 15 amino acid of N-end hold 15 amino-acid residues identical with the N-shown in the SEQ ID NO:2 as a result.Rna helicase enzyme 52.80 production of antibodies that embodiment 6 anti-ATP rely on
Rna helicase enzyme 52.80 specific polypeptide with the synthetic following A TP dependence of Peptide synthesizer (PE company product):
NH2-Met-Ala-Ala-Ala-Asp-Gly-Ser-Leu-Phe-Asp-Asn-Pro-Arg-Thr-Phe-COOH(SEQ?ID?NO：7)。Form compoundly with hemocyanin and bovine serum albumin coupling this polypeptide respectively, method is referring to Avrameas, et al.Immunochemistry, 1969; 6:43.Add the complete Freund's adjuvant immunizing rabbit with the above-mentioned hemocyanin polypeptide complex of 4mg, add the incomplete Freund's adjuvant booster immunization once with the hemocyanin polypeptide complex again after 15 days.Employing is done the titre that ELISA measures antibody in the rabbit anteserum through the titer plate of 15 μ g/ml bovine serum albumin polypeptide complex bag quilts.From the rabbit anteserum of antibody positive, separate total IgG with albumin A-Sepharose.Polypeptide is incorporated on the Sepharose4B post of cyanogen bromide-activated, from total IgG, separates anti-peptide antibody with affinity chromatography.Immuno-precipitation proof antibody purified can combine with the rna helicase enzyme 52.80 that ATP relies on specifically.Embodiment 7: polynucleotide passage of the present invention is as the application of hybridization probe
Picking out suitable oligonucleotide fragment from polynucleotide of the present invention is of use in many ways as hybridization probe, as can whether containing polynucleotide sequence of the present invention and detect the homologous polynucleotide sequence to identify it with the healthy tissues of different sources or the genome or the hybridization of cDNA library of pathological tissue with this probe, whether further also available this probe in detecting polynucleotide sequence of the present invention or the expression of its homologous polynucleotide sequence in healthy tissues or pathological tissue cell be unusual.
The purpose of present embodiment is to pick out suitable oligonucleotide fragment as hybridization probe from polynucleotide SEQ ID NO:1 of the present invention, and identifies in some tissues whether contain polynucleotide sequence of the present invention or its homologous polynucleotide sequence with the filter hybridization method.The filter hybridization method comprises dot blotting, Southern blotting, Northern blotting and copy method etc., and they all are that polynucleotide sample to be measured is fixed on use essentially identical step crossover in back on the filter membrane.These identical steps are: the filter membrane of having fixed sample at first carries out prehybridization with the hybridization buffer that does not contain probe, so that nonspecific combining site suppressed by vector of sample and synthetic polymer institute are saturated on the filter membrane.Prehybridization solution is contained the hybridization buffer replacement of label probe then, and insulation makes probe and target nucleic acid hybridization.After the hybridization step, the probe in the hybridization is not removed by a series of film steps of washing.Present embodiment utilizes the film condition of washing (as than low salt concn and higher temperature) of higher-strength, so that hybrid context reduces and only keep the signal of high specificity.The probe that present embodiment is selected for use comprises two classes: first kind probe be fully with the identical or complementary oligonucleotide fragment of polynucleotide SEQ ID NO:1 of the present invention; The second class probe is part and the identical or complementary oligonucleotide fragment of polynucleotide SEQ ID NO:1 of the present invention.Present embodiment selects for use dot blotting that sample is fixed on the filter membrane, higher-strength wash under the film condition, the hybridization specificity of first kind probe and sample is the strongest and kept.One, probe selects for use
From polynucleotide SEQ ID NO:1 of the present invention, select oligonucleotide fragment as hybridization probe, the several aspects that should follow following principle and need to consider: 1, the probe size preferable range is a 18-50 Nucleotide; 2, GC content is 30%-70%, and surpassing then, non-specific hybridization increases; 3, probe interior should not have complementary region; 4, what meet above condition can be used as the primary election probe, further do the computer sequential analysis then, comprise this primary election probe is carried out homology relatively with its source sequence area (being SEQ ID NO:1) and other known genome sequence and complementary district thereof respectively, if with the homology in non-target molecule zone greater than 85% or there are 15 continuous bases of surpassing identical, then this primary election probe is general just should not use; 5, whether the primary election probe finally is chosen to be the probe of actual application value also should further be determined by experiment.
Select and synthetic following two probes after finishing the analysis of above each side:
Probe 1 (probe1) belongs to first kind probe, and complete homology of gene fragment or the complementation (41Nt) of SEQ ID NO:1:
5’-TGGCAGCCGCCGACGGTTCGCTCTTCGACAACCCCAGGACG-3’(SEQ?ID?NO：8)
Probe 2 (probe2) belongs to the second class probe, is equivalent to gene fragment or its complementary segmental replacement mutant nucleotide sequence (41Nt) of SEQ ID NO:1:
5’-TGGCAGCCGCCGACGGTTCGCTCTTCGACAACCCCAGGACG-3’(SEQ?ID?NO：9)
Other unlisted common agents and the compound method thereof relevant with following concrete experimental procedure please refer to document: DNA PROBES G.H.Keller; M.M.Manak; Stockton Press, 1989 (USA) and molecular cloning laboratory manual books more commonly used are as works such as " molecular cloning experiment guide " (second edition in 1998) [U.S.] Sa nurse Brooker, Science Press.
Specimen preparation: 1, from fresh or frozen tissue, extract DNA
Step: 1) the fresh or fresh normal liver tissue that thaws is put into the plate that is immersed on ice and fills phosphate buffered saline buffer (PBS).With scissors or scalpel tissue is cut into small pieces.Should keep organizing moistening in the operation.2) with 1000g centrifugal chopper tissue 10 minutes.3) with cooled homogenate damping fluid (0.25mol/L sucrose; 25mmol/LTris-HCl, pH7.5; 25mmol/LnaCl; 25mmol/L MgCl 2) precipitation that suspends (approximately 10ml/g).4) 4 ℃ with electric homogenizer homogenate tissue suspension at full speed, until tissue by broken fully.5) 1000g is centrifugal 10 minutes.6) with re-suspended cell precipitation (the initial tissue sample of every 0.1g adds 1-5ml), centrifugal 10 minutes again with 1000g.7) with the resuspended precipitation of lysis buffer (the initial tissue sample of every 0.1g adds 1ml), connect following phenol extraction process then.2, the phenol extraction process of DNA
Step: 1) wash cell, centrifugal 10 minutes of 1000g with the cold PBS of 1-10ml.2) with the sedimentary cell (1 * 10 of cold cell pyrolysis liquid resuspension 8The minimum of applications 100ul lysis buffer of cell/ml).3) adding SDS is 1% to final concentration, if before re-suspended cell SDS is directly joined in the cell precipitation, cell may form big agglomerate and be difficult to fragmentation, and the overall yield that reduces.This point is in extracting＞10 7Especially severe during cell.4) add Proteinase K to final concentration 200ug/ml.5) 50 ℃ of insulation reaction 1 hour or 37 ℃ gently jolting spend the night.6) use equal-volume phenol: chloroform: primary isoamyl alcohol (25: 24: 1) extracting, in little centrifuge tube centrifugal 10 minutes.Two corresponding clear separation, otherwise carry out centrifugal again.7) water is transferred to new pipe.8) use the equal-volume chloroform: primary isoamyl alcohol (24: 1) extracting, centrifugal 10 minutes.9) water that will contain DNA is transferred to new pipe.Carry out purifying and the ethanol sedimentation of DNA then.3, the purifying of DNA and ethanol sedimentation
Step: 1) 1/10 volume 2mol/L sodium-acetate and 2 times of cold 100% ethanol of volume are added in the dna solution mixing.-20 ℃ of placements 1 hour or to spending the night.2) centrifugal 10 minutes.3) careful sucking-off or pour out ethanol.4) with 70% cold ethanol 500ul washing precipitation, centrifugal 5 minutes.5) careful sucking-off or pour out ethanol.With the cold washing with alcohol precipitation of 500ul, centrifugal 5 minutes.6) careful sucking-off or pour out ethanol is inverted on thieving paper then residual ethanol is flow to end.Dry air 10-15 minute, so that the volatilization of surperficial ethanol.Note not making the precipitation complete drying, otherwise dissolve again than difficulty.7) with small volume TE or the resuspended DNA precipitation of water.The low speed vortex vibrates or uses the dropper pressure-vaccum, increases TE gradually simultaneously, is mixed to DNA and fully dissolves, every 1-5 * 10 6Cell extracted approximately adds 1ul.
Below the 8-13 step only be used for must removing when depolluting, otherwise can directly carry out the 14th step.8) RNA enzyme A is added in the dna solution, final concentration is 100ug/ml, and 37 ℃ are incubated 30 minutes.9) add SDS and Proteinase K, final concentration is respectively 0.5% and 100ug/ml.37 ℃ are incubated 30 minutes.10) use isopyknic phenol: chloroform: primary isoamyl alcohol (25: 24: 1) extractive reaction liquid, centrifugal 10 minutes.11) carefully shift out water, use isopyknic chloroform: primary isoamyl alcohol (24: 1) extracting again, centrifugal 10 minutes.12) carefully shift out water, add 1/10 volume 2mol/L sodium-acetate and the cold ethanol of 2.5 volumes, mixing put-20 ℃ 1 hour.13) with 70% ethanol and 100% washing with alcohol precipitation, dry air, resuspended nucleic acid, process is with the 3-6 step.14) measure A 260And A 280To detect purity and the productive rate of DNA.15) deposit in-20 ℃ after the packing.The preparation of sample film: 1) get 4 * 2 suitably nitrocellulose filters (NC film) of size, mark point sample position and sample number thereon gently with pencil, each probe needs two NC films, so that wash film with high strength condition and strength condition respectively in the experimental procedure of back.2) draw and contrast respectively 15 microlitres, put on the sample film, dry at room temperature.3) place infiltration that 0.1mol/LNaOH is arranged, last 5 minute of filter paper (twice) of 1.5mol/LNaCl, drying to place to soak into has 0.5mol/L Tris-HCl (pH7.0), last 5 minute of filter paper (twice) of 3mol/LNaCl, dries.4) be sandwiched in the clean filter paper, wrap, 60-80 ℃ of vacuum-drying 2 hours with aluminium foil.
The mark 1 of probe) 3 μ lProbe (0.1OD/10 μ l) add 2 μ lKinase damping fluids, 8-10uCi γ- 32P-dATP+2UKinase is to add to final volume 20 μ l.2) 37 ℃ are incubated 2 hours.3) add the tetrabromophenol sulfonphthalein indicator (BPB) of 1/5 volume.4) cross Sephadex G-50 post.5) to having 32Before washing out, P-Probe begins to collect first peak (available Monitor monitoring).6) 5/pipe, collect the 10-15 pipe.7) with liquid glimmer instrument monitoring isotopic weight 8) merge and be required preparation behind the collection liquid of first peak 32P-Probe (second peak for free γ- 32P-dATP).
Prehybridization
The sample film is placed plastics bag, and adding 3-10mg prehybridization solution (10 * Denhardt ' s; 6 * SSC, 0.1mg/mlCT DNA (calf thymus DNA).), seal sack after, 68 ℃ of water-baths were shaken 2 hours.
Hybridization
Plastics bag is cut off one jiao, adds the probe prepare, seal sack after, 42 ℃ of water-baths are shaken and are spent the night.
Wash film: high strength is washed film:
1) good sample film has been hybridized in taking-up.
2) 2 * SSC among the 0.1%SDS, washes 15 minutes (2 times) for 40 ℃.
3) 0.1 * SSC among the 0.1%SDS, washes 15 minutes (2 times) for 40 ℃.
4) 0.1 * SSC among the 0.1%SDS, washes 30 minutes (2 times) for 55 ℃, and room temperature is dried.Low strength is washed film:
1) good sample film has been hybridized in taking-up.
2) 2 * SSC among the 0.1%SDS, washes 15 minutes (2 times) for 37 ℃.
3) 0.1 * SSC among the 0.1%SDS, washes 15 minutes (2 times) for 37 ℃.
4) 0.1 * SSC among the 0.1%SDS, washes 15 minutes (2 times) for 40 ℃, and room temperature is dried.
X-light autography:
-70 ℃, X-light autography (the compressing tablet time decides according to hybridization spot radioactivity is strong and weak).
Experimental result:
Adopt low strength to wash the hybrid experiment that the film condition is carried out, more than two strong and weak not obviously differences of probe hybridization spot radioactivity; And adopting high strength to wash the hybrid experiment that the film condition is carried out, the hybridization spot radioactive intensity of probe 1 obviously is better than the radioactive intensity of another probe hybridization spot.Thereby available probe 1 is qualitative and analyze existence and the differential expression of polynucleotide of the present invention in different tissues quantitatively.
Sequence table (1) general information: (ii) (iii) sequence number of the rna helicase enzyme 52.80 that relies on of denomination of invention: ATP and encoding sequence thereof: the information of 9 (2) SEQ ID NO:1: (i) sequence signature:
(A) length: 1996bp
(B) type: nucleic acid
(C) chain: two strands
( D ) ： ( ii ) ：cDNA ( xi ) ：SEQ ID NO：1： 1 GGGGCCCAGCAGTCTGCGCACCGGGCTCGCTGCTGCACCACGCGTCACCCACGCAGACCA 61 TGGCAGCCGCCGACGGTTCGCTCTTCGACAACCCCAGGACGTTCTCCAGACGTCCCCCAG121 CCCAGGCGAGTCGGCAAGCAAAGGCTACGAAAAGAAAATACCAAGCGTCCAGTGAGGCTC181 CCCCAGCGAAACGGAGGAACGAAACTTCATTTCTCCCAGCCAAGAAAACTAGTGTTAAAG241 AAACTCAGAGGACTTTTAAGGGGAACGCACAAAAAATGTTTTCTCCAAAGAAGCATTCGG301 TTAGCACAAGTGATAGAAACCAGGAGGAGAGACAGTGCATTAAGACTTCATCACTGTTTA361 AAAACAACCCTGACATTCCAGAACTCCACAGACCTGTGGTAAAGCAGGTGCAAGAAAAAG421 TGTTTACTTCAGCTGCTTTTCATGAGCTGGGCCTCCACCCACATTTAATTTCCACAATAA481 ATACGGTCTTAAAAATGTCTAGTATGACCAGTGTTCAGAAGCAAAGTATTCCTGTGTTGC541 TGGAAGGCAGAGATGCTCTCGTGAGATCCCAGACGGGCTCAGGTAAAACTCTTGCCTATT601 GCATCCCTGTGGTCCAGTCCCTTCAAGCAATGGAGTCAAAAATACAGCGCAGTGATGGCC661 CCTATGCCCTGGTGCTCGTGCCAACGAGAGAGCTAGCTCTACAAAGCTTTGACACTGTCC721 AGAAACTGCTTAAGCCTTTCACCTGGATTGTGCCTGGAGTGTTAATGGGAGGAGAGAAGA781 GAAAATCAGAAAAGGTCAGACTCCGCAAAGGAATAAATATCCTTATCTCAACTCCTGGAC841 GCCTGGTGGATCATATAAAATCCACAAAGAACATTCATTTTAGTCGGCTGCGGTGGTTGG901 TGTTTGATGAAGCAGACAGAATCTTGGATTTGGGTTTTGAAAAGGACATCACAGTGATAC 961 TTAATGCTGTAAATGCTGAATGCCAAAAACGACAGAATGTCTTGCTATCAGCGACACTCA1021 CAGAAGGTGTAACGCGGCTAGCTGATATCAGTTTGCATGATCCAGTCAGTATTTCTGTCC1081 TGGACAAGAGCCATGACCAGTTGAACCCAAAGGACAAAGCGGTCCAGGAGGTCTGTCCTC1141 CACCAGCTGGCGACAAGCTGGACAGCTTTGCAATACCAGAGAGTCTCAAGCAGCATGTGA1201 CTGTGGTTCCCAGCAAACTGAGGCTTGTCTGCCTAGCGGCCTTCATCCTTCAGAAATGCA1261 AGTTTGAGGAAGACCAGAAGATGGTTGTCTTTTTCTCAAGTTGCGAGCTGGTGGAGTTCC1321 ACTACAGCCTCTTCCTACAGACCCTGCTGAGCAGCTCAGGGGCGCCGGCATCAGGGCAGT1381 TGCCATCTGCCTCCATGCGATTAAAATTCCTACGGCTGCATGGCGGCATGGAGCAGGAGG1441 AAAGAACAGCAGTGTTTCAGGAATTTTCACATTCCAGAAGAGGCGTCCTTCTTTGCACGT1501 GAAGAACTCACCCTAAGCCAGAGGAAAGGAACCTTGCTTTTAATACCATCATTATGTTGA1561 CGAGTTGATAAGAAGTACCACCGAATGGCCGGAAAATGGAGTTTCTAAGCCACCTGATTT1621 TAAGGCTGACATTAGGTTTTCTGTTGGTCTCCGGTGGCTGTCCTTGATTGTCCCTGGATG1681 GAGTGCAGTCACCTTTTTCCCAGAAAGGAAAGATACCTGCAGCCCGCCCTGGGCGCCAAC1741 TGTCCCTTGGCATCCTCCTTGGCTGTCCGGCGCGTGCATTTCTTTTTCAGAAGATGCACC1801 TAAATCACCTGTGCTGCTTTCCTCCACCTTCTCCGTATTTTTTTCCGCTTGAAGCATACT1861 GTTCTGTCTGTGCAGTTCTTAATTTCCTCTCCTCCTGGGGAATTTCCACCGTGCCAGGAG1921 GCTAGGAGACAAAGGAGATACGGCTGTGAAGAGTCACAATGTCAGTTCTGTGTCCCAAAT1981 AAATGTAGACTTTCGT ( 3 ) SEQ ID NO：2： ( i ) ：
(A) length: 480 amino acid
(B) type: amino acid
( D ) ： ( ii ) ： ( xi ) ：SEQ ID NO：2： 1 Met Ala Ala Ala Asp Gly Ser Leu Phe Asp Asn Pro Arg Thr Phe16 Ser Arg Arg Pro Pro Ala Gln Ala Ser Arg Gln Ala Lys Ala Thr31 Lys Arg Lys Tyr Gln Ala Ser Ser Glu Ala Pro Pro Ala Lys Arg46 Arg Asn Glu Thr Ser Phe Leu Pro Ala Lys Lys Thr Ser Val Lys61 Glu Thr Gln Arg Thr Phe Lys Gly Asn Ala Gln Lys Met Phe Ser76 Pro Lys Lys His Ser Val Ser Thr Ser Asp Arg Asn Gln Glu Glu 91 Arg Gln Cys Ile Lys Thr Ser Ser Leu Phe Lys Asn Asn Pro Asp106 Ile Pro Glu Leu His Arg Pro Val Val Lys Gln Val Gln Glu Lys121 Val Phe Thr Ser Ala Ala Phe His Glu Leu Gly Leu His Pro His136 Leu Ile Ser Thr Ile Asn Thr Val Leu Lys Met Ser Ser Met Thr151 Ser Val Gln Lys Gln Ser Ile Pro Val Leu Leu Glu Gly Arg Asp166 Ala Leu Val Arg Ser Gln Thr Gly Ser Gly Lys Thr Leu Ala Tyr181 Cys Ile Pro Val Val Gln Ser Leu Gln Ala Met Glu Ser Lys Ile196 Gln Arg Ser Asp Gly Pro Tyr Ala Leu Val Leu Val Pro Thr Arg211 Glu Leu Ala Leu Gln Ser Phe Asp Thr Val Gln Lys Leu Leu Lys226 Pro Phe Thr Trp Ile Val Pro Gly Val Leu Met Gly Gly Glu Lys241 Arg Lys Ser Glu Lys Val Arg Leu Arg Lys Gly Ile Asn Ile Leu256 Ile Ser Thr Pro Gly Arg Leu Val Asp His Ile Lys Ser Thr Lys271 Asn Ile His Phe Ser Arg Leu Arg Trp Leu Val Phe Asp Glu Ala286 Asp Arg Ile Leu Asp Leu Gly Phe Glu Lys Asp Ile Thr Val Ile301 Leu Asn Ala Val Asn Ala Glu Cys Gln Lys Arg Gln Asn Val Leu316 Leu Ser Ala Thr Leu Thr Glu Gly Val Thr Arg Leu Ala Asp Ile331 Ser Leu His Asp Pro Val Ser Ile Ser Val Leu Asp Lys Ser His346 Asp Gln Leu Asn Pro Lys Asp Lys Ala Val Gln Glu Val Cys Pro361 Pro Pro Ala Gly Asp Lys Leu Asp Ser Phe Ala Ile Pro Glu Ser376 Leu Lys Gln His Val Thr Val Val Pro Ser Lys Leu Arg Leu Val391 Cys Leu Ala Ala Phe Ile Leu Gln Lys Cys Lys Phe Glu Glu Asp406 Gln Lys Met Val Val Phe Phe Ser Ser Cys Glu Leu Val Glu Phe421 His Tyr Ser Leu Phe Leu Gln Thr Leu Leu Ser Ser Ser Gly Ala436 Pro Ala Ser Gly Gln Leu Pro Ser Ala Ser Met Arg Leu Lys Phe451 Leu Arg Leu His Gly Gly Met Glu Gln Glu Glu Arg Thr Ala Val466 Phe Gln Glu Phe Ser His Ser Arg Arg Gly Val Leu Leu Cys Thr ( 4 ) SEQ ID NO：3 ( i )
(A) length: 24 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): oligonucleotide (xi) sequence description: information (i) sequence signature of SEQ ID NO:3:GGGGCCCAGCAGTCTGCGCACCGG 24 (5) SEQ ID NO:4
(A) length: 24 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): oligonucleotide (xi) sequence description: information (i) sequence signature of SEQ ID NO:4:ACGAAAGTCTACATTTATTTGGGA 24 (6) SEQ ID NO:5
(A) length: 33 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): oligonucleotide (xi) sequence description: information (i) sequence signature of SEQ IDNO:5:CCCCATATGATGGCAGCCGCCGACGGTTCGCTC 33 (7) SEQ ID NO:6
(A) length: 33 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): oligonucleotide (xi) sequence description: the information of SEQ ID NO:6:CATGGATCCTCACGTGCAAAGAAGGACGCCTCT 33 (8) SEQ ID NO:7:
(i) sequence signature:
(A) length: 15 amino acid
(B) type: amino acid
(D) topological framework: linearity is molecule type (ii): polypeptide (xi) sequence description: information (i) sequence signature of SEQ ID NO:7:Met-Ala-Ala-Ala-Asp-Gly-Ser-Leu-Phe-Asp-Asn-Pro-Arg-Thr-Phe 15 (9) SEQ ID NO:8
(A) length: 41 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): oligonucleotide (xi) sequence description: information (i) sequence signature of SEQ ID NO:8:TGGCAGCCGCCGACGGTTCGCTCTTCGACAACCCCAGGACG 41 (10) SEQ ID NO:9
(A) length: 41 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): oligonucleotide (xi) sequence description: SEQ ID NO:9:TGGCAGCCGCCGACGGTTCGCTCTTCGACAACCCCAGGACG 41

Claims (18)

1, the rna helicase enzyme 52.80 of a kind of isolated polypeptide-ATP dependence is characterized in that it includes: the polypeptide of the aminoacid sequence shown in the SEQ IDNO:2 or the active fragments of its polypeptide, analogue or derivative.
2, polypeptide as claimed in claim 1, the aminoacid sequence that it is characterized in that described polypeptide, analogue or derivative has the homogeny with the aminoacid sequence at least 95% shown in the SEQ ID NO:2.
3, polypeptide as claimed in claim 2 is characterized in that it comprises the polypeptide with the aminoacid sequence shown in the SEQ ID NO:2.
4, a kind of isolating polynucleotide is characterized in that described polynucleotide comprise to be selected from down a kind of in the group: (a) coding has the polypeptide of aminoacid sequence shown in the SEQ ID NO:2 or its fragment, analogue, derivative
Polynucleotide; (b) with polynucleotide (a) complementary polynucleotide; Or (c) and (a) or the polynucleotide of at least 70% homogeny (b) are arranged.
5, polynucleotide as claimed in claim 4 is characterized in that described polynucleotide comprise the polynucleotide that coding has aminoacid sequence shown in the SEQID NO:2.
6, polynucleotide as claimed in claim 4, the sequence that it is characterized in that described polynucleotide include the sequence of 1-1996 position among the sequence of 60-1502 position among the SEQ IDNO:1 or the SEQ ID NO:1.
7, a kind of recombinant vectors that contains exogenous polynucleotide is characterized in that it is the recombinant vectors that is formed by the described polynucleotide of arbitrary claim among the claim 4-6 and plasmid, virus or vehicle expression vector establishment.
8, a kind of genetically engineered host cell that contains exogenous polynucleotide is characterized in that it is to be selected from following a kind of host cell:
(a) host cell that transforms or transduce with the described recombinant vectors of claim 7; Or
(b) host cell that transforms or transduce with the described polynucleotide of the arbitrary claim among the claim 4-6.
9, a kind of preparation method with rna helicase enzyme 52.80 active polypeptide of ATP dependence is characterized in that described method comprises: (a) under rna helicase enzyme 52.80 conditions of expressing the ATP dependence, cultivate the described through engineering approaches host cell of claim 8; (b) from culture, isolate rna helicase enzyme 52.80 active polypeptide with ATP dependence.
10, a kind of can with polypeptide bonded antibody, it is characterized in that described antibody is the rna helicase enzyme 52.80 specificity bonded antibody that can rely on ATP.
11, the compound of an analoglike or adjusting polypeptide active or expression is characterized in that they are simulation, promotion, antagonism or the active compound that suppresses the rna helicase enzyme 52.80 of ATP dependence.
12, compound as claimed in claim 11 is characterized in that it is the polynucleotide sequence shown in the SEQ ID NO:1 or its segmental antisense sequences.
13, the described application of compound of a kind of claim 11, it is characterized in that described compound be used to regulate rna helicase enzyme 52.80 that ATP relies in vivo, the method for external activity.
14, a kind of disease relevant or method of disease susceptibility of detecting with the described polypeptide of arbitrary claim among the claim 1-3, it is characterized in that it comprises the described polypeptide expression amount that detects, perhaps detect the activity of described polypeptide, perhaps detect and cause described expression of polypeptides amount or active unusual nucleotide diversity in the polynucleotide.
15,, it is characterized in that it is applied to screen stand-in, the agonist of the rna helicase enzyme 52.80 that ATP relies on, antagonist or inhibitor as the application of polypeptide as described in the arbitrary claim among the claim 1-3; Perhaps be used for the peptide finger print identification.
16, as the application of the described nucleic acid molecule of arbitrary claim among the claim 4-6, it is characterized in that it is used for nucleic acid amplification reaction as primer, perhaps be used for hybridization, perhaps be used to make gene chip or microarray as probe.
17,, it is characterized in that forming with safe and effective dosage and pharmaceutically acceptable carrier the pharmaceutical composition of the relevant unusually disease of the rna helicase enzyme that relies on as diagnosis or treatment and ATP 52.80 with described polypeptide, polynucleotide or its stand-in, agonist, antagonist or inhibitor as the described polypeptide of arbitrary claim, polynucleotide or application of compound in claim 1-6 and 11.
18, the described polypeptide of arbitrary claim, polynucleotide or the application of compound among the claim 1-6 and 11 is characterized in that being used for the treatment of medicine as fetal development deformity, tumour, diabetes, menoxenia, peptide ulceration, irregular pulse, anaemia, epilepsy with described polypeptide, polynucleotide or compound.
CN 00125083 2000-09-07 2000-09-07 A novel polypeptide-adenosine triphosphate dependent ribonucleic acid uncoiling enzyme 52.80 and polynucleotide for coding said polypeptide Pending CN1341740A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN 00125083 CN1341740A (en) 2000-09-07 2000-09-07 A novel polypeptide-adenosine triphosphate dependent ribonucleic acid uncoiling enzyme 52.80 and polynucleotide for coding said polypeptide

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN 00125083 CN1341740A (en) 2000-09-07 2000-09-07 A novel polypeptide-adenosine triphosphate dependent ribonucleic acid uncoiling enzyme 52.80 and polynucleotide for coding said polypeptide

Publications (1)

Publication Number Publication Date
CN1341740A true CN1341740A (en) 2002-03-27

Family

ID=4590882

Family Applications (1)

Application Number Title Priority Date Filing Date
CN 00125083 Pending CN1341740A (en) 2000-09-07 2000-09-07 A novel polypeptide-adenosine triphosphate dependent ribonucleic acid uncoiling enzyme 52.80 and polynucleotide for coding said polypeptide

Country Status (1)

Country Link
CN (1) CN1341740A (en)

Similar Documents

Publication Publication Date Title
CN1330080A (en) Polypeptide-human protein 10 containing P structure domain and polynucleotide for coding it
CN1381476A (en) Polypeptide-human tumor endothelial marker -30.69 and polynucleotide for coding it
CN1333274A (en) Novel polypeptide--human GARP protein 12.98 and polynucleotide for encoding said polypeptide
CN1341618A (en) A novel polypeptide-human RNA conjugated protein 21.12 and polynucleotide for coding said polypeptide
CN1339481A (en) New polypeptide-human PHD zine finger protein 34.84 and polynucleotide for encoding such polypeptide
CN1341740A (en) A novel polypeptide-adenosine triphosphate dependent ribonucleic acid uncoiling enzyme 52.80 and polynucleotide for coding said polypeptide
CN1339478A (en) New polypeptide-human L1 factor ORF 2 relative protein 10.78 and polynucleotide for encoding such polypeptide
CN1341621A (en) A novel polypeptide-human U2 snRNP accessory factor small subunit 26-24.86 and polynucleotide for coding said polypeptide
CN1339480A (en) New polypeptide-human C2H2 type zinc finger protein 11.99 and polynucleotide for encoding such polypeptide
CN1341721A (en) A novel polypeptide-human reverse transcriptive enzyme 9.13 and polynucleotide for coding said polypeptide
CN1341722A (en) A novel polypeptide-human RNA polymerase III subunit 21.45 and polynucleotide for coding said polypeptide
CN1376686A (en) Polypeptide-indenture protein-34.32 and polynucleotide for coding it
CN1352194A (en) New polypeptide-human leucine zipper protein 10.01 and polynucleotide for encoding such polypeptide
CN1340520A (en) Polypeptide-polyadenylate bindin 33.11 and polynucleotide for coding it
CN1341654A (en) A novel polypeptide-human zinc finger (ZNF 75) protein 24-19.58 and polynucleotide for coding said polypeptide
CN1343682A (en) Polypeptide-zinc finger protein 41 (ZNF 41) 58.74 and polynucleotide for coding it
CN1329056A (en) Polypeptide-human L1 factor p40 protein 23 and polynucleotide for coding it
CN1341630A (en) A novel polypeptide-human pancreatic island cell antigen p69 (ICAp69)28-9.13 and polynucleotide for coding said polypeptide
CN1329057A (en) A novel polypeptide-human MBLL zinc finger protein 39 and polynucletoide for coding this polypeptide
CN1339598A (en) New polypeptide-human ATP dependent RNA spiral enzyme 20.24 and polynucleotide for encoding such polypeptide
CN1341642A (en) A novel polypeptide-human Hsmarl protein 15.95 and polynucleotide for coding said polypeptide
CN1341624A (en) A novel polypeptide-human syndecan 4 related protein 16.39 and polynucleotide for coding said polypeptide
CN1341658A (en) A novel polypeptide-human cyclin-E conjugated protein (Ceb1) 113-70.07 and polynucleotide for coding said polypeptide
CN1338469A (en) Polypeptide-human L1 factor ORF2 related protein 10.45 and polynucleotide for coding it
CN1382702A (en) Polypeptide-embryo development function associated protein -16.28 and polynucleotide for coding it

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication